Each tablet contains: Rosuvastatin 10 mg Micronized Fenofibrate 160 mg

Turbovas F Tablets combine Rosuvastatin, a potent HMG-CoA reductase inhibitor, with Micronized Fenofibrate, a PPARα agonist, to provide comprehensive lipid management in patients with combined hyperlipidaemia. Rosuvastatin effectively lowers LDL cholesterol and total cholesterol, while Fenofibrate primarily reduces triglyceride levels and increases HDL cholesterol. This dual-action therapy improves the overall lipid profile and helps reduce cardiovascular risk when used alongside appropriate dietary and lifestyle modifications.

Turbovas F Tablets are indicated for the treatment of combined hyperlipidaemia in patients with normal hepatic and renal function.

Rosuvastatin is a selective and competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme involved in cholesterol biosynthesis. By reducing hepatic cholesterol synthesis, it increases hepatic LDL receptor expression and enhances the clearance of circulating low-density lipoprotein (LDL) cholesterol, thereby lowering LDL cholesterol and reducing cardiovascular risk. Micronized Fenofibrate is converted to its active metabolite, fenofibric acid, which activates peroxisome proliferator-activated receptor alpha (PPARα). Activation of PPARα enhances lipoprotein lipase activity, promotes the breakdown of triglyceride-rich lipoproteins, reduces apolipoprotein C-III production, and increases the clearance of triglyceride-rich particles from plasma. These actions lead to reduced triglyceride levels and increased HDL cholesterol.

The recommended dose is one tablet once daily, taken orally after food, at any convenient time of the day, or as directed by the physician.

Turbovas F Tablets are contraindicated in patients with known hypersensitivity to Rosuvastatin, Fenofibrate, or any component of the formulation. They are also contraindicated in patients with active liver disease, gallbladder disease, unexplained persistent elevations in hepatic transaminase levels, severe renal impairment, including patients receiving dialysis, and in pregnant or breastfeeding women.